IgG4 and the COVID Vaccine: What You Need to Know

Repeated mRNA COVID-19 vaccination triggers a gradual shift in the type of antibodies your immune system makes against the spike protein, with a notable rise in a subclass called IgG4. In one widely cited study, the share of spike-targeting antibodies that were IgG4 climbed from a negligible fraction after two doses to roughly a fifth of all spike-specific antibodies after a third mRNA dose. This phenomenon has generated both legitimate scientific interest and considerable alarm online, but the reality is more layered than either “nothing to worry about” or “your immune system is broken.” Whether this shift meaningfully weakens protection, is a harmless sign of immune maturation, or sits somewhere in between depends on details that researchers are still working out.

What IgG4 Does in a Healthy Immune System

Your body makes four subclasses of the most common antibody type, IgG. The first three, IgG1, IgG2, and IgG3, are generally more inflammatory. They are good at flagging pathogens for destruction by immune cells and activating the complement system, a set of proteins that punch holes in invaders. IgG4 is the odd one out. It is the least abundant subclass in the blood and the least aggressive. It interacts poorly with the receptors on immune cells that trigger killing, and it barely activates complement.¹ It also has a distinctive structural quirk: its arms can swap between different IgG4 molecules, creating antibodies that bind to two different targets at once but only weakly to each, which limits the formation of large immune complexes.²

These anti-inflammatory properties serve a purpose. In people undergoing allergen immunotherapy, for instance, the immune system gradually shifts toward producing IgG4 antibodies against the allergen. Those IgG4 molecules compete with IgE, the antibody class responsible for allergic reactions, and help block the overblown inflammatory response that causes symptoms like sneezing and hives.³ So IgG4 is not inherently dangerous. In the right context, it is a tool the immune system uses to dial down inflammation when full-bore aggression is not needed. The concern with COVID vaccines centers on whether that dial-down happens at a time when you still want robust defenses.

How mRNA Vaccination Shifts the Antibody Mix

The landmark observation came from a 2022 study that tracked antibody subclass composition in people who received BNT162b2 (Pfizer) mRNA vaccines. Right after the second dose, the spike-specific antibody response was dominated by IgG1 and IgG3, the pro-inflammatory subclasses you would expect after a fresh vaccination. But several months later, IgG4 began creeping up. After a third mRNA dose, spike-specific IgG4 rose from an average of about 0.04% of all spike-targeting antibodies to roughly 19% late after the third shot.⁴ The researchers also looked at the memory B cells responsible for making these antibodies and found that a substantial fraction of spike-binding memory B cells had switched to producing IgG4, far beyond what you would see in the general memory B cell population.

This class switch was accompanied by measurable changes in what the antibodies could do. The spike-specific antibodies from people with high IgG4 levels were less effective at triggering two key immune functions: phagocytosis, where immune cells engulf infected cells, and complement deposition, where the complement system marks targets for destruction.⁴ Subsequent studies confirmed the pattern. A 2024 paper on bivalent mRNA boosters found that post-booster responses were primarily composed of IgG2 and IgG4 with poor ability to trigger those same Fc-mediated immune functions.⁵

Why mRNA Vaccines Specifically

The IgG4 shift is not a universal feature of all COVID vaccines. It appears strongly linked to the mRNA platform. The original 2022 study explicitly noted that this switch to IgG4 was not observed after vaccination with adenoviral-vector vaccines, such as AstraZeneca’s or Johnson & Johnson’s.⁴ Another study looking at the subclass profiles across different vaccination histories found that the shift toward IgG4 and IgG2 appeared almost exclusively in people who had received only mRNA vaccines or who were infected after mRNA vaccination.⁶

What drives this platform difference is not fully understood. Researchers have suggested that the way mRNA vaccines deliver antigen, essentially instructing your cells to produce spike protein continuously for some period after injection, may create conditions of high and prolonged antigen exposure that favor IgG4 switching. Three factors seem to matter: the concentration of antigen the immune system encounters, the number of repeated exposures, and the type of vaccine platform used.⁷ A broader review noted that IgG4 shifts have been documented in response to other repeatedly administered vaccines as well, including some targeting pertussis, HIV, and malaria, suggesting this is not unique to COVID but may reflect a general immunological response to certain dosing patterns.⁸ One early example is the HIV vaccine trial VAX003, where repeated protein boosts drove a strong IgG4 response that was associated with weaker immune function and a failed clinical outcome.⁹

Do IgG4 Antibodies Still Protect You

This is where the picture gets genuinely complicated, because different studies have reached different conclusions depending on which aspect of protection they measured. IgG4 antibodies are clearly worse at the “effector” side of immune defense. Spike-specific IgG4 monoclonal antibodies were unable to trigger antibody-dependent cellular cytotoxicity (the process where immune cells kill infected cells) and showed reduced phagocytosis and complement activity.¹⁰ On its own, that sounds alarming.

But IgG4 is not the only subclass your body makes. When researchers from Moderna looked at total IgG function, rather than isolating the IgG4 fraction, they found that the overall mix of antibodies maintained strong effector functions after repeated mRNA-1273 dosing. The IgG4 antibodies themselves showed enhanced binding affinity and potent virus-neutralizing ability, complementing the IgG1-driven response rather than undermining it.¹¹ In other words, even though IgG4 alone is poor at flagging cells for destruction, it can still block the virus from getting into cells in the first place, and the other subclasses continue to do the heavier immune work.

The tension between these findings is real and not yet resolved. Some researchers interpret the data as showing that the immune system co-evolves multiple subclasses to maintain balanced protection, with IgG4 contributing neutralization while IgG1 and IgG3 handle the killing functions. Others point out that the overall IgG picture might look reassuring while the IgG4 shift still tilts the balance in a direction that could matter at the margins, particularly for people whose other immune responses are already compromised.

Breakthrough Infections and Clinical Evidence

The question most people care about is straightforward: does the IgG4 shift mean you are more likely to get infected? Here the evidence is mixed. One study found that elevated IgG4 levels after booster vaccination were significantly associated with a higher risk of breakthrough infection, with a roughly 1.8-fold increase in risk for every tenfold rise in IgG4 levels.¹² A higher ratio of non-inflammatory to inflammatory antibody subclasses also correlated with reduced neutralization in that cohort.

But another study, which specifically compared boosted individuals with and without IgG4 switching, found that the presence of IgG4 antibodies in previously infection-naive people did not reduce virus-neutralizing responses in the lab, and breakthrough infection rates were comparable between those with and without IgG4 switching.¹³ Both vaccinated-naive and previously infected vaccinated participants had breakthrough infections within a year, with no statistically significant difference between them.

These results are not necessarily contradictory. The first study measured the correlation between IgG4 levels and subsequent infections across a population, while the second looked specifically at whether the presence of IgG4 itself changed neutralization or infection rates. It is possible that high IgG4 is a marker for a broader immune profile that happens to be less protective, without being the direct cause of increased susceptibility. Disentangling correlation from causation remains a significant challenge in this field.

Why Prior Infection Changes the Story

One of the more interesting findings is that people who were infected with COVID before being vaccinated seem to develop less of an IgG4 shift than people who were vaccinated without any prior infection. A 2025 study compared groups that had the same total number of vaccinations and infections but in different orders. Those who were vaccinated first and then infected showed significantly higher IgG4 levels than those who were infected first and then vaccinated. The researchers concluded that hybrid immunity, where natural infection comes before vaccination, appears to limit the IgG4 increase that follows repeated antigen exposure.¹⁴

People who were infected before vaccination also tend to produce stronger mucosal antibody responses, including IgA in the nose and airways where the virus actually enters.¹⁵ This matters because IgG4, whether helpful or harmful, is a bloodstream antibody. The first line of defense against a respiratory virus involves the mucosal immune system, which mRNA vaccines injected into the arm do not train as effectively as natural infection does. Much of the protection gap people attribute to IgG4 may actually reflect limitations of intramuscular vaccination in general, regardless of which subclass ends up dominating.

Immune Imprinting Limits Variant Coverage

A separate but related concern is that the IgG4 antibodies produced after mRNA vaccination are heavily biased toward recognizing the original Wuhan strain’s spike protein. Even after updated boosters, about 90% of IgG4 antibodies targeting newer variants like BA.1 or XBB.1.5 were still cross-reactive with the ancestral spike, suggesting they were made by memory B cells that were first trained on the original strain rather than newly generated cells tuned to the variant.¹⁶ This phenomenon, called immune imprinting, means the IgG4 fraction may be particularly poor at neutralizing the newest circulating variants.

Some evidence suggests that switching to a different vaccine platform for boosters could partially overcome this imprinting. One study found that an updated XBB.1.5 protein subunit vaccine could partially break through the imprinted IgG4 and effector function patterns established by mRNA priming, while ancestral-strain boosters of any type could not.¹⁷ This has practical implications for how future booster strategies are designed: not just updating the strain but potentially alternating the delivery platform.

IgG4-Related Disease Is a Different Thing

Online discussions often conflate two distinct concepts: the rise in IgG4 antibodies targeting the spike protein and IgG4-related disease, a chronic inflammatory condition in which IgG4-producing immune cells infiltrate and damage organs like the pancreas, salivary glands, and bile ducts. These are not the same phenomenon, and the connection between vaccine-induced IgG4 antibodies and IgG4-related disease remains speculative.

A handful of case reports have described people developing IgG4-related disease shortly after mRNA vaccination. One involved a 78-year-old woman who developed swelling in her submandibular glands and pancreas two weeks after her second Pfizer dose, with blood tests showing elevated IgG4 levels and imaging consistent with the disease.¹⁸ Another case involved autoimmune pancreatitis with significantly elevated serum IgG4 after mRNA vaccination.¹⁹ In both instances the authors acknowledged that the temporal relationship could be coincidental. Case reports can flag potential associations, but they cannot establish causation, and with hundreds of millions of vaccine doses administered worldwide, rare events that would have happened anyway will inevitably cluster near vaccination by chance alone.

IgG4-related disease is driven by tissue-infiltrating plasma cells and fibrosis, not simply by having more IgG4 in your blood. Having elevated spike-specific IgG4 circulating after vaccination is immunologically distinct from having rogue IgG4-producing cells invading your pancreas. Anyone concerned about symptoms like unexplained organ swelling, jaundice, or persistent salivary gland enlargement should see a doctor regardless of vaccination status, but the vaccine-IgG4 literature does not currently support the idea that mRNA vaccination routinely causes IgG4-related disease.

Children, Older Adults, and Individual Variation

The IgG4 class switch is not limited to any single age group. In children aged 5 to 11 who received BNT162b2, IgG4 levels targeting spike protein components increased significantly by one year after the second dose, mirroring the pattern seen in adults.²⁰ In older adults, the picture is similar but with some differences in timing. One study found that older individuals showed increased IgG4 after a third dose and a further rise after a fifth, with a corresponding decrease in the ability of their spike-specific antibodies to activate natural killer cells.²¹

The older-adult finding is worth paying attention to because aging already weakens several arms of the immune system. If repeated mRNA boosting adds an IgG4-mediated reduction in natural killer cell activation on top of age-related immune decline, the cumulative effect could be more consequential in this group than in younger, immunologically robust people. A narrative review raised related concerns for immunocompromised individuals, noting that multiple mRNA doses may result in higher IgG4 levels and could also impair T-cell activation in these populations.²² These are populations where booster strategy decisions carry the most weight, and they are also the populations where the data is thinnest.

What Researchers Are Actually Debating

The scientific conversation around vaccine-induced IgG4 is not a simple argument between vaccine advocates and skeptics. It is a genuine immunological puzzle with thoughtful researchers on multiple sides. The core disagreement comes down to interpretation. One camp sees the IgG4 shift as a natural consequence of repeated antigen exposure: the immune system is calming down its inflammatory response to a protein it has seen multiple times, just as it does during allergy immunotherapy. In this view, the IgG4 antibodies are still functional, still neutralize virus, and the effector function losses are compensated by other subclasses that remain active.

The opposing camp argues that the IgG4 shift represents a form of immune tolerance to the spike protein that could be counterproductive during an actual infection. Under this framework, the immune system has been trained to treat the spike protein as something to tolerate rather than something to attack aggressively, potentially allowing the virus to replicate with less resistance.⁷ The fact that repeated mRNA vaccination has been associated with reductions in phagocytosis and complement activity lends some support to this concern.²³

What both sides agree on is that the phenomenon is real, specific to mRNA platforms, dose-dependent, and worthy of attention in vaccine design going forward. The question is not whether the IgG4 shift happens but whether it matters clinically, and for whom.

IgG4 in Other Primates

An underappreciated wrinkle in this story is that human IgG4 behaves differently from its equivalent in other primates. While non-human primates do produce an IgG4-equivalent subclass, primate IgG4 has been described as inflammatory, with the ability to trigger Fc-mediated immune responses that human IgG4 cannot.²⁴ Comparative studies of IgG subclasses across primates have shown that the molecular evolution of human IgG4 diverged from that of IgG2 and IgG3 in great apes, with chimpanzee IgG4 cross-reacting strongly with human IgG4 antibodies while orangutan and gibbon versions do not.²⁵ Macaques, frequently used in vaccine research, appear to lack a true IgG3 analog entirely and have only three of the four human IgG subclasses.²⁶

This matters for vaccine development because much of the preclinical safety and immunogenicity testing for mRNA vaccines was conducted in macaques. If macaques do not produce a functionally equivalent IgG4, they would not have flagged the IgG4 class switch during animal testing. It is a reminder that immune responses seen in animal models do not always predict what happens in humans, and that some signals can only emerge from large-scale human studies conducted after a vaccine is already in use.